-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Mi25NyTTQnFIPYm8/wmCBzhLodJDcVxnvO5r5aE1Rc8zr4Clym1bfr5K9cuqUM0t
 cSKAPo9Rfu7RJNj3tp22jQ==

<SEC-DOCUMENT>0000950137-04-007574.txt : 20040909
<SEC-HEADER>0000950137-04-007574.hdr.sgml : 20040909
<ACCEPTANCE-DATETIME>20040909123843
ACCESSION NUMBER:		0000950137-04-007574
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20040908
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20040909
DATE AS OF CHANGE:		20040909

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AASTROM BIOSCIENCES INC
		CENTRAL INDEX KEY:			0000887359
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				943096597
		STATE OF INCORPORATION:			MI
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22025
		FILM NUMBER:		041022199

	BUSINESS ADDRESS:	
		STREET 1:		24 FRANKL LLOYD WRIGHT DR
		STREET 2:		PO BOX 376
		CITY:			ANN ARBOR
		STATE:			MI
		ZIP:			48106
		BUSINESS PHONE:		7349305555
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a01737e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>Aastrom Biosciences, Inc.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<HR size="4" noshade color="#000000" style="margin-top: -5px">
<HR size="1" noshade color="#000000" style="margin-top: -10px">





<P align="center" style="font-size: 14pt"><B>UNITED STATES SECURITIES AND EXCHANGE COMMISSION</B>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>


<P align="center" style="font-size: 10pt"><HR align="center" size="1" noshade width="25%">


<P align="center" style="font-size: 18pt"><B>Form&nbsp;8-K</B>


<P align="center" style="font-size: 10pt"><B>CURRENT REPORT<BR>
PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B>



<P align="center" style="font-size: 10pt">Date of report (date of earliest event reported):<BR>
<B>September&nbsp;8, 2004</B>


<P align="center" style="font-size: 24pt"><B>Aastrom Biosciences, Inc.</B>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="85%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="31%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Michigan</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>0-22025</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>94-3096597</B></TD>
</TR>

<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction of<BR>
incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission File No.)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(I.R.S. Employer Identification<BR>
No.)</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>24 Frank Lloyd Wright Drive<BR>
P.O. Box 376<BR>
Ann Arbor, Michigan 48106</B><BR>
(Address of principal executive offices)



<P align="center" style="font-size: 10pt">Registrant&#146;s telephone number, including area code:<BR>
<B>(734)&nbsp;930-5555</B>


<P align="left" style="font-size: 10pt">Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:



<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17
CFR 230.425)</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17
CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="right"><FONT face="Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR>

</TABLE>


<P>
<HR size="1" noshade color="#000000" style="margin-top: -2px">
<HR size="4" noshade color="#000000" style="margin-top: -10px">






<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD></TD><TD colspan="8"><A HREF="#000">Item&nbsp;2.02 Results of Operations and Financial Condition.</A></TD></TR>
<TR><TD></TD><TD colspan="8"><A HREF="#001">Item&nbsp;9.01 Financial Statements and Exhibits.</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="a01737exv99w1.htm">EXHIBIT 99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link2 "Item&nbsp;2.02 Results of Operations and Financial Condition." -->
<DIV align="left"><A NAME="000"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;2.02 Results of Operations and Financial Condition.</B>


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;On September&nbsp;8, 2004, we issued a press release announcing financial
results and operational achievements for our fourth fiscal quarter and fiscal
year ended June&nbsp;30, 2004. A copy of the press release is attached hereto as
Exhibit&nbsp;99.1.


<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to General Instruction B.2 of Form 8-K, this report and the
exhibit are not deemed to be &#147;filed&#148; for purposes of Section&nbsp;18 of the
Securities Exchange Act of 1934, nor shall this report and the exhibit be
incorporated by reference into our filings under the Securities Act of 1933 or
the Securities Exchange Act of 1934, except as expressly set forth by specific
reference in such future filing.

<!-- link2 "Item&nbsp;9.01 Financial Statements and Exhibits." -->
<DIV align="left"><A NAME="001"></A></DIV>

<P align="left" style="font-size: 10pt"><B>Item&nbsp;9.01 Financial Statements and Exhibits.</B>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="3%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right"><B>(c)</B></TD>
    <TD width="1%">&nbsp;</TD>
    <TD><B>Exhibits.</B></TD>
</TR>

</TABLE>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="55%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="11%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="84%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit No.</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Press Release dated September&nbsp;8, 2004</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>


<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<P align="center" style="font-size: 10pt"><B>SIGNATURES</B>



<P align="left" style="font-size: 10pt">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.


<P align="left" style="font-size: 10pt">Date: September&nbsp;8, 2004


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top">&nbsp;</TD>
    <TD colspan="3"><B>AASTROM BIOSCIENCES, INC.</B><BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000">/s/ Alan M. Wright
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Alan M. Wright&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2">Senior Vice President,
Administrative and
Financial Operations, CFO&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt">2
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a01737exv99w1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>Aastrom Biosciences, Inc.</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<P align="left" style="font-size: 10pt"><IMG src="a01737a0173700.gif" alt="(AASTROM LETTERHEAD)">

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="10%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="56%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>

<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom">
    <TD colspan="3" valign="top" align="left">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;FOR IMMEDIATE RELEASE</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;CONTACTS:
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Kris M. Maly or
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Kevin McGrath</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Becky Anderson
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Cameron Associates</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Investor Relations Department
</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: (212)&nbsp;245-4577</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Aastrom Biosciences, Inc.</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">Phone: (734)&nbsp;930-5777</TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><B>AASTROM BIOSCIENCES, INC. REPORTS FOURTH QUARTER 2004<BR>
FINANCIAL RESULTS</B>




<P align="left" style="margin-left:3%; font-size: 10pt"><B>Ann Arbor, Michigan, September&nbsp;8, 2004 &#151; </B>Aastrom Biosciences, Inc. (NasdaqSC:
ASTM) today reported financial results for the fourth quarter and fiscal year
ended June&nbsp;30, 2004. The Company also reported significant achievements during
the last quarter and fiscal year, both clinically and operationally. For the
quarter ended June&nbsp;30, 2004, these achievements included:


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Expanding U.S. Phase I/II clinical trial for bone fractures to
include a second site. We added The University of Michigan Health
System&#146;s orthopedic trauma center for the trial of our bone generation
Tissue Repair Cell (TRC)&nbsp;adult stem cell product. We expect a third
clinical site to be included in this trial for patients with severe
tibial leg fractures</TD>
</TR>

</TABLE>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Appointing James A. Cour President and Chief Operating Officer on
July 6th, strengthening senior management&#146;s operational expertise.
Previously Mr.&nbsp;Cour held executive level management positions with
Baxter International, Windsor VanGelder Limited and Cytomedix</TD>
</TR>

</TABLE>



<P align="left" style="margin-left:3%; font-size: 10pt">&#147;Aastrom achieved a significant number of milestones in fiscal year 2004, led
by the expansion and advancement of our clinical trials for patient treatment
and our product development pipeline,&#148; commented R. Douglas Armstrong, Ph.D.,
Chief Executive Officer and Chairman of Aastrom. &#147;We are demonstrating
material progress toward our goal of generating a focused portfolio of adult
stem cell-based products for the regenerative repair of damaged human tissues
that have substantial therapeutic and commercial potential. I believe fiscal
year 2005 is going to be an important year in our evolution from the research
and development phase into the commercialization phase as we expand the
clinical evaluation of our adult stem cell-based TRCs for tissue regeneration,
and begin to report on the results.&#148;



<P align="left" style="margin-left:3%; font-size: 10pt">Other significant highlights during the 2004 fiscal year included the
following:


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Received the Company&#146;s first TRC-related FDA approved
Investigational New Drug (IND)&nbsp;application for a multi-center clinical
trial for local bone repair, followed by the initiation of our lead
clinical trial site in Chicago, IL</TD>
</TR>

</TABLE>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Commenced European Union (EU)&nbsp;bone graft clinical studies with
BG-Kliniken &#145;Bergmannsheil&#146; Ruhr-University Hospital in Germany and the
Hospital General de l&#146;Hospitalet in Barcelona, Spain. These studies
utilize our proprietary bone-forming TRCs in combination with
commercial synthetic matrix products to treat non-union large bone
fractures</TD>
</TR>

</TABLE>


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Issued a patent by the U.S. Patent and Trademark Office that covers
a method of bone marrow transplantation, often referred to as stem cell
transplants, using cells produced with our proprietary single-pass
perfusion technology</TD>
</TR>

</TABLE>


<P align="center" style="font-size: 10pt">-more-




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="right" style="font-size: 10pt">Aastrom-4<SUP>th</SUP> Q<BR>
September&nbsp;8, 2004<BR>
Page 2


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Awarded a Phase I SBIR grant by the NIH for the development of a
bone marrow stem cell-based treatment of circulation ischemia caused by
vascular diseases and diabetes</TD>
</TR>

</TABLE>



<P align="left" style="margin-left:3%; font-size: 10pt"><B>Fourth Quarter and Twelve Months ended June&nbsp;30, 2004 Results</B>



<P align="left" style="margin-left:3%; font-size: 10pt">Total revenue for the quarter ended June&nbsp;30, 2004, consisting of product sales
and rentals in the EU and grants, was $0.2&nbsp;million, unchanged from the same
period in fiscal year 2003. Total revenue for the twelve months ended June&nbsp;30,
2004 was $1.3&nbsp;million compared to $0.8&nbsp;million for the same period in fiscal
year 2003.



<P align="left" style="margin-left:3%; font-size: 10pt">Net loss for the quarter ended June&nbsp;30, 2004 was $2.7&nbsp;million, or $.03 per
share, compared to a net loss of $2.7&nbsp;million, or $.05 per share for the same
period in fiscal year 2003. Net loss for the twelve months ended June&nbsp;30,
2004, was $10.5&nbsp;million, or $.14 per share, compared to $9.6&nbsp;million, or $.19
per share for the same period in fiscal year 2003.



<P align="left" style="margin-left:3%; font-size: 10pt">At June&nbsp;30, 2004, the Company had $16.9&nbsp;million in cash, cash equivalents and
marketable securities as compared to $10.5&nbsp;million in cash, cash equivalents
and marketable securities at June&nbsp;30, 2003.



<P align="left" style="margin-left:3%; font-size: 10pt">&#147;Our financial condition continues to be strong. The Company&#146;s cash position
and our controlled level of expenditures allow us to advance our ongoing bone
grafting clinical trials, and move forward with the planned expansion of our
clinical trials program,&#148; said Alan M. Wright, Senior Vice President
Administrative and Financial Operations and Chief Financial Officer of Aastrom.



<P align="left" style="margin-left:3%; font-size: 10pt">Total costs and expenses for the quarter ended June&nbsp;30, 2004 were $3.0&nbsp;million,
compared to $2.9&nbsp;million for the same period in fiscal year 2003. Total costs
and expenses for the twelve months ended June&nbsp;30, 2004 increased to $12.0
million, compared to $10.6&nbsp;million for the same period in fiscal year 2003.



<P align="left" style="margin-left:3%; font-size: 10pt">Research and development expenses for the quarter ended June&nbsp;30, 2004 increased
slightly to $1.8&nbsp;million, from $1.5&nbsp;million for the same period in fiscal year
2003. Research and development expenses for the twelve months ended June&nbsp;30,
2004 increased to $6.3&nbsp;million, compared to $5.6&nbsp;million for the same period in
fiscal year 2003. These increases reflect our continued research and product
development activities in the area of tissue regeneration, including our
on-going and planned bone grafting clinical trials in the United States and the
EU.



<P align="left" style="margin-left:3%; font-size: 10pt">Selling, general and administrative expenses increased slightly to $1.2&nbsp;million
for the quarter ended June&nbsp;30, 2004, compared to $1.1&nbsp;million for the same
period in fiscal year 2003. Selling, general and administrative expenses
increased to $5.4&nbsp;million for the twelve months ended June&nbsp;30, 2004, from $4.0
million for the same period in fiscal year 2003. The increase in these
expenses resulted from continued expansion of business and clinical trial
activities in the EU, and additional capital raising expenses not related to
specific transactions. Selling, general and administrative expenses for fiscal
year ended June&nbsp;30, 2004 also include a non-cash charge of $53,000 relating to
certain warrants issued in August&nbsp;2003 for public and investor relations
services and a $372,000 non-cash charge related to an employee
performance-based stock option that vested in September&nbsp;2003.



<P align="left" style="margin-left:3%; font-size: 10pt">Dr.&nbsp;Armstrong concluded, &#147;After serving with distinction for the past 6&nbsp;years
we regretfully report that on August&nbsp;5, 2004, Mary Lincoln Campbell resigned
from our Board and as audit committee chairperson, due to the requirements of
her other business commitments. We thank Mary for her many contributions and
for her devotion to helping guide the Company through important issues over the
years.&#148;


<P align="center" style="font-size: 10pt">-more-




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="right" style="font-size: 10pt">Aastrom-4<SUP>th</SUP> Q<BR>
September&nbsp;8, 2004<BR>
Page 3



<P align="left" style="margin-left:3%; font-size: 10pt"><B>Outlook for the Coming Year</B>



<P align="left" style="margin-left:3%; font-size: 10pt">Aastrom entered fiscal year 2005 with sufficient funding to support planned
clinical and operational goals and objectives, including:


<P>

<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Continue the accrual of patients in our current FDA multi-center
bone graft trial in the U.S., and add a third institution as a clinical
site</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Complete the first phase of clinical studies in the EU for bone
grafting repair of severe non-union fractures; pending positive
results, move toward commercialization</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Initiate and complete a jaw bone reconstruction clinical trial in
the EU for sinus lift procedures for dental implants</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Prepare for and initiate an EU clinical study utilizing TRCs to
regenerate vascular tissue in patients with diabetic limb ischemia</TD>
</TR>

<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="6%" style="background: transparent">&nbsp;</TD>
    <TD width="1%" nowrap align="right">&#149;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pursue applicable opportunities for grants, to further define
potential uses and applications for our proprietary technology and cell
products</TD>
</TR>

</TABLE>



<P align="left" style="margin-left:3%; font-size: 10pt"><B>Aastrom Conference Call Information</B>



<P align="left" style="margin-left:3%; font-size: 10pt">R. Douglas Armstrong, Ph.D., Chief Executive Officer and Chairman, James A.
Cour, President and Chief Operating Officer, and Alan M. Wright, Senior Vice
President Administrative &#038; Financial Operations and Chief Financial Officer of
Aastrom Biosciences, Inc., will review and discuss the fourth quarter fiscal
year 2004 financial results and the Company&#146;s recent progress and future goals
today, September&nbsp;8, 2004, at 11:00&nbsp;a.m. (EDT)&nbsp;when they will host a conference
call. Interested parties should call (785)&nbsp;832-1508, or toll-free (800)
540-0559, fifteen minutes before the start of the call to register and identify
themselves as registrants of the &#145;Aastrom Conference Call&#146;. The call will be
simulcast on the web at
http://phx.corporate-ir.net/playerlink.zhtml?c=85924&#038;s=wm&#038;e=938425, and the
entire call will be archived for replay at the same site for 90&nbsp;days.



<P align="left" style="margin-left:3%; font-size: 10pt"><B>About Aastrom Biosciences, Inc.</B>



<P align="left" style="margin-left:3%; font-size: 10pt">Aastrom Biosciences, Inc. (NasdaqSC: ASTM) is developing proprietary stem
cell-based products for the regenerative repair of damaged human tissues and
other medical disorders. Aastrom&#146;s strategic position in the tissue
regeneration and cell therapy sectors is enabled by its proprietary Tissue
Repair Cells (TRCs), a mix of bone marrow stem and progenitor cells, and the
AastromReplicell&#174; System, an industry-unique automated cell production platform
used to produce cells for clinical use. Together TRCs and the AastromReplicell
System provide a foundation that the Company is leveraging to produce multiple
Prescription Cell Products (PCPs), the first of which is now in the clinical
stage in the U.S. and EU.



<P align="left" style="margin-left:3%; font-size: 10pt">TRCs are the core component of the PCPs Aastrom is developing for the bone
grafting, peripheral vascular disease and cartilage markets. The Company also
markets the AastromReplicell System and disposable dendritic cell production
kits to researchers and institutions developing vaccines to treat cancer and
infectious diseases, under its Cell Production Products line.



<P align="left" style="margin-left:3%; font-size: 10pt">For more information, visit Aastrom&#146;s website at www.aastrom.com.


<P align="center" style="font-size: 10pt">-more-




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="right" style="font-size: 10pt">Aastrom-4<SUP>th</SUP> Q<BR>
September&nbsp;8, 2004<BR>
Page 4



<P align="left" style="margin-left:3%; font-size: 10pt"><I>This document contains forward-looking statements, including without
limitation, statements concerning clinical trial plans and expectations,
intended product development and commercialization objectives, the expected
adequacy of capital resources to support planned activities, plans for the
current fiscal year, potential product applications, and potential advantages
of the AastromReplicell System and related cell therapy products, which involve
certain risks and uncertainties. The forward-looking statements are also
identified through use of the words &#147;expect,&#148; &#147;planned,&#148; &#147;potential,&#148;
&#147;believe,&#148; and other words of similar meaning. Actual results may differ
significantly from the expectations contained in the forward-looking
statements. Among the factors that may result in differences are the inherent
uncertainties associated with clinical trial and product development
activities, regulatory approval requirements, the availability of resources and
the allocation of resources among different potential uses. </I><B><I>These and other
significant factors are discussed in greater detail in Aastrom&#146;s Annual Report
on Form10-K and other filings with the Securities and Exchange Commission.</I></B>


<P align="center" style="font-size: 10pt">&#151; Financial Table Follows &#151;



<P align="center" style="font-size: 10pt">-more-



<P align="center" style="font-size: 10pt">&nbsp;
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">




<P align="center" style="font-size: 10pt"><B>AASTROM BIOSCIENCES, INC.</B>



<P align="left" style="font-size: 10pt"><B>CONSOLIDATED STATEMENT OF OPERATIONS DATA:</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="47%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="2%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="6%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Quarter ended June 30,</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>Year ended June 30,</B><HR size="1" noshade></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2003</B><HR size="1" noshade></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>2004</B><HR size="1" noshade></TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="7"><B>(Unaudited)</B></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">REVENUES:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Product sales and rentals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">16,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">4,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">314,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">49,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Grants and other</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">159,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">206,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">530,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,253,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:40px; text-indent:-10px">Total revenues</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">175,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">210,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">844,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,302,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">COSTS AND EXPENSES:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Cost of product sales and rentals</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">13,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">145,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">27,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Cost of product sales and rentals &#150; provision
for obsolete and excess inventory</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">303,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">&#151;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">748,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">253,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Research and development</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,479,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,818,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,647,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">6,289,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Selling, general and administrative</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,148,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">1,190,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">4,017,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">5,390,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:40px; text-indent:-10px">Total costs and expenses</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">2,943,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">3,013,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">10,557,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">11,959,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">OTHER INCOME</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">30,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">56,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">134,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">169,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">NET LOSS</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(2,738,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(2,747,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(9,579,000</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(10,488,000</TD>
    <TD nowrap>)</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">NET LOSS PER SHARE</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:30px; text-indent:-10px">(Basic and Diluted)</DIV></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(.05</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(.03</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(.19</TD>
    <TD nowrap>)</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="right">$</TD>
    <TD align="right">(.14</TD>
    <TD nowrap>)</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">Weighted average number of common shares outstanding</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">58,945,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">80,713,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">50,984,000</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">73,703,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:30px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="left" style="font-size: 10pt"><B>CONSOLIDATED BALANCE SHEET DATA:</B>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="65%">

<!-- Begin Table Head --><TR valign="bottom">
    <TD width="77%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="8%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="9%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center" colspan="3"><B>June 30, 2004</B><HR size="1" noshade></TD>
</TR>


<!-- End Table Head -->

<!-- Begin Table Body -->
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:10px; text-indent:-10px">ASSETS:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Cash and investments </DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">16,926,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Other current assets </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">906,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Property, net </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">334,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Total assets </DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">18,166,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:20px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD><DIV style="margin-left:10px; text-indent:-10px">LIABILITIES AND SHAREHOLDERS&#146; EQUITY:</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Current liabilities </DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">558,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR valign="bottom">
    <TD><DIV style="margin-left:20px; text-indent:-10px">Shareholders&#146; equity </DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right">17,608,000</TD>
    <TD>&nbsp;</TD>
</TR>

<TR style="font-size: 1px">
    <TD><DIV style="margin-left:10px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="1" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR valign="bottom" style="background: #eeeeee">
    <TD><DIV style="margin-left:30px; text-indent:-10px">Total liabilities and shareholders&#146; equity </DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="right">$</TD>
    <TD align="right">18,166,000</TD>
    <TD>&nbsp;</TD>
</TR>
<TR style="font-size: 1px">
    <TD><DIV style="margin-left:20px; text-indent:-10px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD align="right"><HR size="4" noshade>&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>


<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"># # #




<P align="center" style="font-size: 10pt">&nbsp;
</DIV>


</BODY>
</HTML>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>a01737a0173700.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 a01737a0173700.gif
M1TE&.#EA-@(Z`/<``````(````"``("`````@(``@`"`@,#`P,#<P*;*\`0$
M!`@("`P,#!$1$186%AP<'"(B(BDI*55554U-34)"0CDY.?]\@/]04-8`D\SL
M_^_6QN?GUJVID#,``&8``)D``,P````S`#,S`&8S`)DS`,PS`/\S``!F`#-F
M`&9F`)EF`,QF`/]F``"9`#.9`&:9`)F9`,R9`/^9``#,`#/,`&;,`)G,`,S,
M`/_,`&;_`)G_`,S_````,S,`,V8`,YD`,\P`,_\`,P`S,S,S,V8S,YDS,\PS
M,_\S,P!F,S-F,V9F,YEF,\QF,_]F,P"9,S.9,V:9,YF9,\R9,_^9,P#,,S/,
M,V;,,YG,,\S,,__,,S/_,V;_,YG_,\S_,___,P``9C,`9F8`9ID`9LP`9O\`
M9@`S9C,S9F8S9IDS9LPS9O\S9@!F9C-F9F9F9IEF9LQF9@"99C.99F:99IF9
M9LR99O^99@#,9C/,9IG,9LS,9O_,9@#_9C/_9IG_9LS_9O\`S,P`_P"9F9DS
MF9D`F<P`F0``F3,SF68`F<PSF?\`F0!FF3-FF68SF9EFF<QFF?\SF3.9F6:9
MF9F9F<R9F?^9F0#,F3/,F6;,9IG,F<S,F?_,F0#_F3/_F6;,F9G_F<S_F?__
MF0``S#,`F68`S)D`S,P`S``SF3,SS&8SS)DSS,PSS/\SS`!FS#-FS&9FF9EF
MS,QFS/]FF0"9S#.9S&:9S)F9S,R9S/^9S`#,S#/,S&;,S)G,S,S,S/_,S`#_
MS#/_S&;_F9G_S,S_S/__S#,`S&8`_YD`_P`SS#,S_V8S_YDS_\PS__\S_P!F
M_S-F_V9FS)EF_\QF__]FS`"9_S.9_V:9_YF9_\R9__^9_P#,_S/,_V;,_YG,
M_\S,___,_S/__V;_S)G__\S___]F9F;_9O__9F9F__]F_V;__Z4`(5]?7W=W
M=X:&AI:6ELO+R[*RLM?7U]W=W>/CX^KJZO'Q\?CX^/_[\*"@I("`@/\```#_
M`/__````__\`_P#______RP`````-@(Z```(_@#_"1Q(L*#!@P@3*EPX8>&_
M(10H3("PSJ'%BPCI8=S(L:/'CR!#BAQ)LJ3)DRA3JES)LB5"=@HF.92DH&8$
MEPO?-<3)LZ?/GT"#"AU*M"C1>0J&`+&W$&:$FN^&3E!PTZC5JUBS:MW*M2O/
M=0K2`'&TT(&">!440!AJ=HC7MW#CRIU+M^Y'>0J(`-G;*R%-"?]H*H`G]$%2
MNX@3*U[,N+%)"6'W`DF3\.D!@35W+J0W3YYGC9L]?Q[H.9[A"/1$>QY(KYT\
M@9SCS3/(>73">0?BL:;'.2-OWHZ#"Q].?#&\O)+W;CAX0.U`?#4)9V1'P6Q-
M!0PH1#W(K@*#ZS6'_K2)]QV\^0<'J-?4O0Y">(+W)EBO":'-9=;L)GR__(["
M`P8..%!!.P1),L%_`$:`3W$,-NC@@T%%T$!R0(SS#U,%I;7=/_,81@%"QV%G
M7SSQ'-"&3:`)]$Y-#T@"#XGPP*2`?>^\8Q8$!]18XP$'0*?``_(,8=YKS:G5
MSHOQO',B5;K](X\D[BEP``5J#2%!!.4-P9N0#%@YQ'RO02CFF&26:=&*15`X
MCST6%,3+CP4M&69!S4F0XD`A`B90D9(<A-2'`AGFUD%@#:$.50?``T]4,FY(
M4#Q4,G#?/RNJI8"C\APZXXGKS";0/#(":N:HI);*H`,/B"49)?]8`$1?_@--
MQ4Y!]-2D#G</)-1.3?<)V49"]S`PD*`(^:A`103)..=!FH99J0*\,'O=K`;)
M.*FIV&:K+5SW*)!F<A?N11EL-=TIT%0*>$I0C0F%2&U-?684;:"''>3C6@2%
MZ"A"-0%:J:ATTF>N0/*8M>"V"">LL%#S+*!4<JR.LZI`)Q[LIJT<Q5/3K__T
M>Q&Q]D)5D)":*=0HI351:U">E=6[\,LPQUP26&@D1UDO%-HSCUGOQ*/HSR^Z
MQX"Z%NTZHT!I*5#!M0B!;!!T##1),+P6A?AKI4SC61.!"#WE@,Q@ARVV0PI0
M0&%?1E!H@8SFM:V`Q04MRDX;$PQ1WL8$"UD3_@,2L-/S04X7!+74*)]E$3U/
MN84UB%1W#>?8D$<.M@0+I"W9S11.QNL\G'?N.94*%)3IW7M7@`\[9G$LT#U8
MGC<>08$3-/BZ-2VKD)"*\\JX`O$>]%2ND@<OO+9OZI5<7ZHF5\3CP-9D\;/J
MM)-;BO08IOI`N+6CSE/761S[<]@1OKA%4^4NY>Z]&_3[\.RW7V9:R0/QQC^4
M9`[$4UPKY-X#&M5:=KMX4PBHRG.?[PED=@,IDLH40@\A5:!P61-(B-)7D/6Y
M[X(8'$YSC"<9C=AO>0\P`H824BD"56I>!ZG4]1*"EZ/]PX#_0.!`WN,0I!P+
M@NAK&?`RR,,>V@4"_JE*3IM<E;FTZ&5^"TG:/Y25D*3]2AYZ2LA4;O5"EPDN
M?%?DG4-\%*WQK:QQOF.>#\=(QJV@*6?VL%\::J(J6.D**EX,6`#/EY#O<`V&
M,B18>6Q'JYH\$(<'F:`.RTC(0AI%:11BU1OL)Z0'2,8(9/N1_P95D!4]P'H"
M>0KA6(.N@3P%7]7"8MRNLR\\66<@<<P7&-4G1D.Z\I4L@<ZWQ/6/#=B/"'Z$
MV$*Z]Z:DO&,VN)D*`WB1EIV`SE'T>(=A)#40&;T.'NWX8](B>`#K3.!:\5@2
M!.8D(PJBLB91+$B'%/`U6)KSG"6I5002^8\+4*@(_HG`$!Z@#C=T$"&2_O!/
M!80D@?BXK0T:J0`$*'(/>*C#,.2<#T4,LB3PX",^#]AG!-K`QR7JC477T0Z>
MVA#1"CA``M>2!SX>,`2!5N`>!I%'!")0@38L$)TPC:E#3F2YO4`29_;+J?P0
M8IO4""1)[/`;/%(T#XVLYA_T@$=ZV"&)`\AC8#^]1U"=RJ&BPF:3XCR`)*8*
M#Z(A]:FPD0?14J.NSOA)(V:5J5K7>C$.\N4?\=-I<HP00;;:]:Z2HU+\YE<_
MN68N#0^H"EX'2]BP'2>(DF&*7S-GA`6DC#;`(0CGXH95>/#"7"4B2&]@PYFQ
M]L^K]#B`NG@SV7P=`*H(*>VG/F4N7DBGL+`M_B/W(J"J-M&C%QK(K6YWRUL-
M6%91*)SA`P8*NP5.)*($@<`$U'$]"0S78NW!'E6&H+(WS<H!*<('`R)`190)
M]+40D(`ZD&61-H#R'T_Y1QLV5#`AH3:V\!W>L]0BE@W8XP)IR*]^][M?-;Q!
MGD,(\$()PKMN$20"O;,14NG8L5E)S<#_>&T[*/D/21W52=]!+VD&$^$$*H`>
M\4B1`@B$U81TAR`G8NJD)O`KV<3WQ1=T6U0DMMC)@*YMP64`!`)\X-[A`U]#
MZ!WK%!#%$Q=DP@2.0#BS^6-**OABU(7/4\+9E#]2[$W7'!9*8<QE]K$-/$[J
M0%S_.H0&N(V&F+E'_JU0"('\-6>H'%Y=8#ZL(@ZCL!V"K15AMOR/>`"&*M*=
MU:2:HR)4_F-77C4QA0$*DTF9ES.O[;*DP38/"@3XTA%`J7FYZP8T\#<-;MC>
MI4<]:@AL2!WJ&`)YU9L^=D`@TP21P`0JD#Y)7%)ED@`HP210@0BH#!Z_.D`X
M#_!J41U@GSB*E00HP&>'S(T@Z]#-!((K@5<'=]+8?IFY0,-MWM3CV]_^C4,B
MNQ&HDENS(!G8>]$M$M2N.]OPCK>\YTWO>MO[WOC.M[[WS6_&O%M;_^ZWP!DH
MCP-<FQ?L\E/!2\S"A50TM1T9F)(Z8CN-9$T=<YI'I$/BU;+>:;,.\<P[_E[S
MCE6'W"++VB0?`PZ;BR15'HH"2:)3>Z<PO9?AJQWX3WCA@!Z5DQZF@SD$O-D<
M89?,9!..2G.`Z)9*L^/A%^O(`_8U<8[L\!\2B-;1_['-@?!BA1N!UC\.,`%V
M5`4FTE$'/M1.,7;4]6G7K(#;J8QBJBB`'?0HNY6YOD!X#.$>%9`VE'3#BPE(
M`C4'GN>L[C'0AJAT"!"(UCX?\%*#D"<];S?(C]P#JFCV3F,&4;MTVD&!^TC@
M2PN$U#LBT"1Z.(`P[Y``Z3D46,'J7"6\&)0#9M,&U17,J_UQ4CEQHY$0$XPU
ME*+B;)KZC](;Y/`4V#@[&""=V=R'<_"P73P@_L+9$G5J4DIE[;7Q,J_C1&M.
MB4*O/%#H*=<V2;2?FL>UE_CZ?ZCC,@^8S?9GH])`_>,>W84G%`!K@C,K\``!
MP"9_!P$<U\,`87(/418K*#5Q&D$!?1(!O)<^JR8)<Y),*'80>%8!KR4/`'-:
M3@(:KW$GLP$/"V)]HD(W!2$)Y#4/YP4W`P%2A\8Q[1`U7/<:$2!6V]$+0CB$
M1%B$1GB$2)B$2KB$3-B$3OB$4!B%4CB%2U@/!L$+-]$.^,*#`_%W!1$/$7``
M$<`HZN!W//(U]Y<O."A!%3$/0W``]R`U\_4H[$!,@:)VP@(EMN8HOY)_]%=Z
MI@:#LB>&]*!=*Z0D_H/2!NK0)\*2>[RP#E/B4D-#=NAU#_CP0)"((QJ##\NV
M+CH1+?`@=YJA)?]W,$,0#X:7<)A!2H*##_0@`?B`%^SP``3"8"H2+_0@@Q+4
M#GY#$!.`4GBF(H!1*RIR/8L8+Y+`BT;5!M)#,?>0/G-(,&/X=.M@(_+P#L)B
M'_!@>P*A#J`1#VFX1%]7$*;&+G,#AVW7;"^D$?#P(>]P`*<X=GUS*_+@4KQ0
M8_B8C_JXC_S8C_[XCP`9D)+A1G@R=>W@*>E"$%Y($/)0`?4(&`^@&]OW#^M0
M`?LB;-!%&$AA<$`B$%\V)YP($[I1`;-1`?0@58'A>[ZV4"4W=CN!(U5Q_CI!
M52WR@(!:Q8M<UWP;\H,/H2@5D2OPH!EMP(&#<G6WLC0Q5(<\^1`:L54",00U
MB0]@>!\:TST%D1_W@%+P`!@FPB$&H1GRT`X3,!O>B`]1,5FY)PD5`"CW`%+T
M("QC]RN3E1L4,"LP)PEN00^\P'.$D1ME-Q`-%6=!4B*>LEXQ9&HYET#Y8U"_
MP@NSXHU553U'`@'@2`'U6!'9!XN1"0'L.)85@8#J=0^Y5U1[Z4@">9JHF9JJ
MN9JLZ5<$*1"Y5Q#,!CL;-R6!`@^[1WMCYP"EY'H:P0M4U'_--R_1B%3J,!OK
M\"LD^0\3D(M1<0^JTP[OP!FA\PX$<@#(`@$0_B@0[2"3!O%`!_``'Y)K.1D!
M*,23(@@/%;$.[&"6]*`.L<>!@+)#[=`W#M`&\``\ZD`MI!A[F>2&NM&>,W0=
MZG@Z>'(KZDDH3--/4\(.5L*"_300NJ@B'P*70=66%G-L!*8N?>-UE-0MUT$:
M?U2/T'D9&E-76Q<ZO?=C[&!0ZA`/G*E>2M(GO`"78W<3ZP!20V!]T=,W?(,7
M`B$!O?,PK5FD1GJD2'JDK_D/O(`O]%`133I4,70KS:@B_/,.:Q&A<T,/^.D`
MZ$<I'])`!.&0U:,N,($>`]$.7`-Z&,AUN3@KDF`QE$1K[[!X-P&/Z"5M/3(K
M["`UP--F8^<6N9(?_B`&HSZH*+\RE-&BH7W3D$A53@H9+<DV!-+Q`)4*<Q_"
M#@3B?'OB'C9(D2KCGUVY#G,2E'C"&1'P6NM`024I&O8W*Q(0%1,P@H3!C$P:
MJ$PJ5I2I@.R)8CHV*6`H$/G$G"-'4;L7#PMDF+!)*7M'9?#Y$/%0>$O4*:_A
M4K(S*\KZ0KH1D3W)"T45`508KN(ZKN1:KN9ZKDTX0J1!+?.@:RRX5?'2BS_E
M4NPP&ZV!DG]S#QNR#BC)I,V&K'6X$`?93#$R&X*F=/&"<`GD=E&1)/?0*1&F
MJ5'QCO]@9?1`+9?E)`MR,$%5K_6Z1!H'J^*U>YKZC*!R0#399R7;3&&R_E1-
MT@Z2X$T(0;&P22"\H&ERB$+OD(R.HHI(Q8N$QU2]LZJ.$B,QZY']*E5NUV?X
MD(PA=S!/V@[Z^@ZP-W)PLT`/A7>L88,7*PE;%K,.Q@[/^#1'VTSZ)['_QXL;
M=WLQ1;,D`6Q!NK9L.[<"-W,A\8O/1K=ZN[<D(59\ZS[Q\*DJ$7`L%TOJ`K-_
MF[AUP5P=(:7,L7>2Q4<P@0_F!78)8:L"9')38VFEY!%H>A!0.1"KRA":J[BF
M^Q-#Z7*QTGIN`C!(U8VEQ`[DU2(9T7*TX2=0RY`45KA0A92[@33<I(X&T:NG
M6[Q`D;H'Q)X(.@&D)P_0B2,\1ZK,2P&\`(;X_D`!4:2>%+`@#R`!\Q"&S?0\
M;J%V;;`@RR41%0D89EEAZS!1@=$WS>F!R:DZ[ZDH3Y)JG4%2\O``;3!1YH5W
MS"6\ODN1^)"<#Z&(.ZJ6ZS`$=>I@Y"6@QAO!/(&\6'@N[R""!6&)6/>D"Y)K
M0DHI1^=Z,LJD9DI>Q^:?ZH>4?IBI44%G:^&'[<`Q'?)QAM<.30*?!8,9&!9A
M2\.-`^&[.I%)6$@8[4F>U1.L4AF^$KS$+8&\!T!%O<<_S22#CZE>U3AR&-R.
M"?10N;*&R0)=^$"YW1B4A!&C5!H5Y?2#58&G5FIE\Z`9U6B102(0:[&_/!Q#
M#E!YOEO`04IVLS&CZ-L1.DNS0!#,Q(9\$M8*8OBR-!\<#_(@+`_[#U_S;!HA
M>TLD*J`I++$Z=F9*1=4T=G^4?]&WCFZX1%$A+-7S0H2Q#A8S&Y`*I,PJH\(9
M.CGL=TC%"X"1/Q4[G;CZ0C49+;'Z;!H:GHXR7EYYR,@L$KDFH._@G:_(GNWJ
M4K]BH)0KE>W:L1(:/>/QQ/,PP.^PB.U`JAX95%$1;>K%&[^RM%`\=NQ)O^7+
M9V],,/NIJ?48I)SQ1*2ZGXJR=P6,#P32L2C%5&'\?T'5!I["C3$<5':;S`Q=
62$="$C[;T!(M4U#'$08]T3H7$```.S\_
`
end

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
